Oyster Point Pharma (NASDAQ:OYST) announced its quarterly earnings data on Tuesday. The company reported ($8.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($7.59), Fidelity Earnings reports.
Shares of NASDAQ OYST opened at $17.49 on Wednesday. Oyster Point Pharma has a 12 month low of $13.26 and a 12 month high of $19.01.
A number of equities research analysts recently commented on the company. JPMorgan Chase & Co. started coverage on Oyster Point Pharma in a report on Monday, November 25th. They set an “overweight” rating and a $26.00 target price for the company. Cowen began coverage on shares of Oyster Point Pharma in a research note on Monday, November 25th. They set an “outperform” rating and a $40.00 price objective for the company. Finally, Piper Jaffray Companies started coverage on shares of Oyster Point Pharma in a report on Monday, November 25th. They issued an “overweight” rating and a $35.00 price objective on the stock.
Oyster Point Pharma Company Profile
Oyster Point Pharma, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. It is involved in developing OC-01, a nicotinic acetylcholine receptor agonist that is in Phase IIb clinical trial to treat the signs and symptoms of dry eye disease, as well as Phase III clinical trial for the neurotrophic keratitis.
Read More: Why is the LIBOR significant?
Receive News & Ratings for Oyster Point Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oyster Point Pharma and related companies with MarketBeat.com's FREE daily email newsletter.